Miles Inc.

Miles Laboratories, Inc.

Bayer Corporation

David L Garling

James P Albarella

Robert P Hatch

Robert T Buckler

Frederick E Ward

The present invention relates to a chromogenic benzoisothiazolone polymer derivative for measuring the presence or appearance of thiols in an aqueous system.

Chromogenic thiol indicating benzoisothiazolone compounds

A process for measuring the presence or appearance of thiols in aqueous system, the process involving contacting the aqueous system with a chromogenic thiol indicating benzoisothiazolone derivative and then observing chromophoric changes due to thiol mediated reduction of the benzoisothiazolone derivative wherein the changes are proportional to the amount or rate of appearance of the thiols in the aqueous system.

Process for determining thiols using chromogenic benzoisothiazolone

Newly synthesized chromogenic thiol-indicating benzoisothiazolone derivatives having the structure: ##STR1## where R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification, are useful in the detection of thiols, particularly in an aqueous system. This process comprises contacting the aqueous system with a chromogenic thiol-indicating benzoisothiazolone derivative as described herein. Chromophoric changes due to thiol-mediated reduction of the benzothiazolone derivative then occur. Such changes can be in a solution or on an indicator surface in contact or having been in contact with the aqueous system. The chromophoric changes, due to a bathochromic shift in characteristic light absorption upon reduction of the benzoisothiazolone derivative, are proportional to the amount or rate of appearance of thiols in the aqueous system.

Chromogenic thiol indicators based on an isobenzothiazolone ring system

Newly synthesized chromogenic thiol-indicating benzoisthiazolone derivatives having the structure: ##STR1## where R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification, are useful in the detection of thiols, particularly in an aqueous system. This process comprises contacting the aqueous system with a chromogenic thiol-indicating benzoisothiazolone derivative as described herein. Chromophoric changes due to thiol-mediated reduction of the benzothiazolone derivative then occur. Such changes can be in a solution or on an indicator surface in contact or having been in contact with the aqueous system. The chromophoric changes, due to a bathochromic shift in characteristics light absorption upon reduction of the benzoisothiazolone derivative, are proportional to the amount or rate of appearance of thiols in the aqueous system.

Compounds which are 3-methylene flavanones and 3-methylene chromanones having activity against microorganisms are disclosed. The compounds are represented by the general structural formula: ##STR1## wherein: R.sup.1 is a member selected from the group consisting of hydrogen, Br, CH.sub.3 and OCH.sub.3 ; R.sup.2 is selected from the group consisting of hydrogen and ##STR2## wherein R.sup.4 is a member selected from the group consisting of hydrogen, Br, Cl, CH.sub.3, OCH.sub.3, NO.sub.2, N(CH.sub.3).sub.3 and CN; R.sup.5 is selected from the group consisting of hydrogen and Cl, with the proviso that when R.sup.5 is Cl, R.sup.4 is hydrogen or Cl; and R.sup.3 is selected from the group consisting of hydrogen, phenyl, 2-thienyl, 4-pyridyl and naphthyl, with the proviso that when R.sup.3 is naphthyl, R.sup.1 and R.sup.2 are hydrogen.

3-Methylene flavanones and 3-methylene chromanones

Analogues of prostaglandins A, E and F in which a phenyl moiety is attached to the C.sub.14 carbon atom are disclosed. Also disclosed are methods of preparing the analogues and starting materials. The compounds have the structural formula: ##STR1## in which J is methylene, R or S-hydroxymethylene or methine; L is methylene or methine and can be methine only when J is methine; M is carbonyl, R or S-hydroxymethylene; Q is ethylene, Z-vinylene or inter-phenylene; T is an alkoxy-carbonyl having from 2 to 3 carbon atoms inclusive, or carboxyl; and B is a loweralkyl of from 1 to 5 carbon atoms. The prostaglandin analogues of the present invention exhibit a separation of pharmacological activity. The analogues can be used for platelet aggregation (and Methyl 14-Phenyl-11.alpha.,15S-dihydroxy-9-oxoprost-13E-en-1-oate can be used for antagonism for smooth muscle stimulation) without the accompanying undesirable side effects of natural prostaglandins, e.g., flush, headache, abdominal cramps and nausea.

Growing community of inventors

Elkhart, IN, United States of America

David L Garling